§ Federal grant opportunity · HT942526RCRPRCDA
DoW Rare Cancers Resource and Community Development Award
JoAnn Martin Grantor is accepting applications for DoW Rare Cancers Resource and Community Development Award. The deadline is November 18, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- JoAnn Martin Grantor
- Application deadline
- November 18, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526RCRPRCDA
Program overview
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) supports the development of research resources and clinical or preclinical datasets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Research supporting this funding opportunity should fill one of the following major gaps: Lack of research and clinical resources, including patient tissues, cell and tumor models. Lack of communication and dissemination strategies within scientific and patient communities for sharing rare cancers research and clinical findings. Lack of infrastructure for sharing data and other resources. Lack of therapeutics and mechanistic research to inform treatment development. Distinctive Features: Documentation of plans for engagement and partnerships with Patient Advocates throughout the life cycle of the research study from development of the research question through execution of the study. Community building and enhancement are key components. A description of the dissemination and sustainability of the platform for scientific and/or clinical and patient community is required. Preliminary data are not required but may be included to address feasibility.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from JoAnn Martin Grantor.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before November 18, 2026, allowing time for registration and validation.
Related grant opportunities
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- DoW Toxic Exposures Clinical Trial Award
- DoW Toxic Exposures Investigator Initiated Research Award
- DoW Toxic Exposures Translational Research Award
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.